AlphAIAlphAI — Financial news for AI agents
MarketBeatMAR 162 min read$SAMG

Silvercrest Asset Management Group (NASDAQ:SAMG) Issues Quarterly Earnings Results

Silvercrest Asset Management Group (NASDAQ:SAMG) has reported its quarterly earnings, missing analyst estimates with an EPS of $0.18 and revenue of $31.96 million. The company declared a quarterly dividend of $0.21, but its high payout ratio of 118.31% raises concerns about its sustainability. SAMG's stock traded down at $14.14 with a market capitalization of $173 million.

Original reporting
MarketBeat · MarketBeat
Published Mar 16, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 16, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Silvercrest Asset Management Group (NASDAQ:SAMG) Issues Quarterly Earnings Results — source image
Source · MarketBeat
Decision brief

The 30-second read

$SAMGBearishMed
01

Why it matters

The earnings miss and high dividend payout ratio have led to a slight stock decline, raising concerns about dividend sustainability and future growth prospects.

02

Market read

The company's earnings performance is a key indicator for investors in the asset management sector, with potential ripple effects on related financial services firms.

03

What to watch

Potential for management to implement cost controls or strategic adjustments that could mitigate earnings shortfall.

Relevance 6/10Timing: Immediate, as earnings impact is current.

Background

Silvercrest Asset Management Group reported quarterly earnings below analyst estimates, citing market volatility and client asset fluctuations.

Company-level read

Ticker impact

$SAMGBearishMedium confidence
Context

The news pertains directly to Silvercrest Asset Management Group, NASDAQ:SAMG.

Expected impact

Potential short-term decline of 3-5% due to earnings miss and dividend concerns.

Evidence & confidence

Earnings miss and high payout ratio suggest caution; however, the stock's modest decline indicates limited immediate downside, and technical support levels may provide some resilience.

Market effects

Sector

The financial advisory and asset management sector may experience slight negative sentiment due to earnings miss in a peer company.

Regional

Limited, as the impact is company-specific.

Global

Negligible, given the company's size and sector.

Counterpoint

What could challenge this read

The earnings miss may be a one-time event; the company's fundamentals remain strong, and the stock could recover in the medium term.

Key entities

  • Company
    Silvercrest Asset Management Group

    A financial services firm specializing in wealth management and investment advisory.

Read at source← All news

Related articles

JUL 30
$SAMGMed

Silvercrest Asset Management Group Inc. Reports Q2 2026 Results

Silvercrest Asset Management Group Inc. (SAMG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silvercrest Asset Management Group Inc. Reports Q2 2026 Results New York, NY – July 30, 2026 - Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and six months ended Ju

SEC EDGAR 8-K6 min
OCT 24
$MRNAHigh

Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

ynetnews.com2 min
OCT 24
$VRTXMed

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

finance.yahoo.com2 min
OCT 24
$CPIXMedAI 8/10

Cumberland Pharma Reports Phase 2a Safety Data For Ifetroban In Systemic Sclerosis; Shares Slide

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

rttnews.com1 min